Saturday, December 7, 2013
New York Marriott Downtown | 85 West St at Albany St | New York, NY 10006
ATTENTION ALL PRESENTERS AND ATTENDEES: THE EPA WILL NOT PROVIDE WIFI IN THE MEETING ROOM. PLEASE REMEMBER TO DOWNLOAD THE MATERIALS FROM THE EPA WEBSITE AND BRING YOUR LAPTOP TO THE CONFERENCE FULLY CHARGED!
EPA President Gary W. Jay, MD, FAAPM
Chief Medical Officer
RAPID Pharmaceuticals, MD and NC, USA
Clinical Urine Drug Testing
John J. Spagnolo, MA, RPh
Manager Clinical Services
North Kingstown, RI
Educational Objectives - Participants will be better able to compare and contrast various matrices used for drug testing; provide justifications for clinical urine drug testing; explain the difference between EIA and LC/MS/MS testing; assess the limitations of point of care testing; and list methods of urine specimen adulteration.
Pain and Cannabinoids
Ethan Russo MD, President
International Cannabinoid Research Society
Educational Objectives - Participants will be able to discuss the latest ongoing research and study outcomes re cannabinoids and pain to determine for themselves if it shows great promise, will explore cannabinoid analgesia via the endo-cannabinoid system and non-receptor systems, discuss current medications even though they are not yet approved for pain, explore synthetic cannabinoids, discuss legalities in varying states and abroad.
Debate: Why Are We Always Just Stuck With Opioids?
Moderator and Panel Member:
Gary W. Jay, MD, FAAPM
Chief Medical Officer
RAPID Pharmaceuticals, MD and NC, USA
Robert L. Barkin, MBA, PharmD, FCP
Professor, Anesthesiology, Pharmacology, and Family Medicine
Rush University Medical College
David C. Deitz, MD, PhD
Vice-President, National Medical Director
Commercial Insurance Strategic Practices
Liberty Mutual Insurance
Educational Objectives - Participants will be better able to determine what opioids can do and how they should be used; give a different medical perspective regarding the best form of evidence based pain medicine treatment which is being ignored (interdisciplinary pain treatment centers), and give an insurance perspective re treating chronic non-cancer pain patients.
Mitochondria – Novel Therapeutic Targets for the Control of Neuropathic Pain
Professor & Canada Senior Research Chair
Educational Objectives - Participants will be better able to describe the clinical presentation of chemotherapy-induced peripheral neuropathy (CIPN), present recent experimental results implicating mitochondrial dysfunction as the cause of CIPN, and discuss the potential of mitochondrial protective drugs for the prevention and treatment of CIPN.
William K. Schmidt, PhD, President
NorthStar Consulting LLC
Linda R. Watkins, PhD
Targeting Glial Activation for Treating Chronic Pain and Improving Opioid Efficacy:
The Promise of XT-101
University of Colorado at Boulder
Darren Wolfe, PhD (PeriphaGen)
Delivery of Endogenous Anti-nociceptive Genes for Local Pain Therapy
President, CEO, Founder
Nadia M.J. Rupniak, PhD
Development of Lasmiditan, a Selective 5-HT1F Receptor Agonist,
as a Novel Acute Therapy for Migraine
Vice President of Research & Development
CoLucid Pharmaceuticals Inc
Gavril W. Pasternak, MD, PhD
Potent Opioid Analgesics Lacking Traditional Side-effects
Anne Burnett Tandy Chair in Neurology
Member and Attending Neurologist
Head, Laboratory of Molecular Neuropharmacology
Memorial Sloan-Kettering Cancer Center
Professor of Neurology & Neuroscience, Pharmacology and Psychiatry
Weill College of Medicine of Cornell University
New York City, NY
Marta Illueca, MD
Update on Opioid Induced Constipation
Executive Director US Medical Affairs
Michael Ruff, PhD
Orally Active Short Peptides that Block Innate Immunity and Prevent or Reverse Hyperalgesia
Chief Scientific Officer
RAPID Pharmaceuticals AG
Pain and Suicide
Martin D. Cheatle, PhD
Director Pain and Chemical Dependency Program
Center for Studies of Addiction
University of Pennsylvania
Educational Objectives - Participants will be better able to identify those patients with high risk characteristics and to prepare clinics to have action plans for interventions for patients identified as being actively suicidal or at high-risk for suicide.
Glial Cells and Pain
John F. Peppin, DO, FACP
Medical Director, Global Pharmaceuticals
We would like to thank
for their support of building and furthering
the goals of the Eastern Pain Association.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical education through the joint sponsorship of the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP) and the Eastern Pain Association Inc. ABQAURP is accredited by the ACCME to provide continuing medical education for physicians.
The American Board of Quality Assurance and Utilization Review Physicians, Inc. designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP) is an approved provider with the Florida Board of Nursing to provide continuing education for nurses. ABQAURP designates this activity for 6.50 nursing contact hours through the Florida Board of Nursing, Provider # 50-94.
This program is approved for Category 2 credit by the American Osteopathic Association.
Pharmacy Accreditation Statement
The CMEsolutions is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 8.0 contact hours (.80 CEUs). ACPE Program Number: 0274-9999-13-021-L04-P
Planners/Faculty Disclosure Summary
The planners and faculty of Eastern Pain Association have indicated they have no relevant financial relationships to disclose in regard to the content of their presentations with the exception of:
• Robert L Barkin, PharmD receives teaching honoraria from Endo Pharmaceuticals
• Thomas Carattini, PharmD receives salary/stock from Horizon Pharma
• Martin D. Cheatle, PhD receives honoraria from Ameritox
• Gary Jay, MD is the CMO of Rapid Pharmaecuticals
• John Peppin, DO, FACP is the Medical Director of Malinckrodt Pharmaceuticals; consultant for INSYS, Nektar,Teva & Zogenix, and BOD of VC Equine Research
• Ethan Russo MD receives consulting fees and stock from GW Pharmaceuticals
The Pharma Roundtable presentation has not been approved for CME or Nursing contact hours but will receive ACPE credits. The individual speaker disclosures will be listed directly on their presentations.
This Activity Is Jointly Sponsored By:
The American Board Of Quality Assurance
and Utilization Review Physicians